Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Hutchison Medipharma Limited
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02897479CT.gov A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Sarcomatoid Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Volitinib (this asset) | Hutchison Medipharma Limited | P2 | CCC · 53 |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | Seoul National University Hospital | P2 | B |
| Durvalumab | Seoul National University Hospital | P2 | B |
| Toripalimab | Sichuan Cancer Hospital and Research Institute | P2 | CCC |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Ivocizumab | Fudan University | P2 | CCC |
| Carboplatin | Sichuan Cancer Hospital and Research Institute | P2 | CCC |
| Pegargiminase | Polaris Group | P1 | CC |
Other indications for Volitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Papillary Renal Cell Carcinoma | — | P3 | BB · 66 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 64 |
| Renal Cell Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, DimerSeoul National University HospitalB
- DurvalumabSeoul National University HospitalB
- ToripalimabSichuan Cancer Hospital and Research InstituteCCC
- IpilimumabNational Cancer Institute (NCI)CCC
- NivolumabNational Cancer Institute (NCI)CCC
Citation
Floatz Terminal. Volitinib in Lung Sarcomatoid Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/volitinib-lung-sarcomatoid-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →